
Cahill Represents Underwriters in Public Offering for Amarin Corporation plc

Date: 07/23/19

Cahill represented the underwriters in connection with the public offering by Amarin Corporation plc of 22,222,223 American Depositary Shares, each representing one ordinary share, resulting in approximately \$400 million of proceeds to Amarin (before underwriting discounts and offering expenses). Amarin is a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health and reduce cardiovascular risk. Proceeds from the offering will be used to support commercialization of Amarin's approved cardiovascular product, Vascepa®, assuming the FDA approves Amarin's requested label expansion, to increase commercial supply of Vascepa, and for general corporate purposes.

Attorneys

- Geoffrey E. Liebmann
- Michael B. Weiss
- Patrick Gordon